欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

休市中 02-13 16:08:09

7.000

+0.100

+1.45%

最高7.000	最低6.780	成交量60.80万
今开6.880	昨收6.900	日振幅3.19%
总市值57.05亿	流通市值57.05亿	总股本8.15亿
成交额416.55万	换手率0.07%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7,"timestamp":1770970089000,"preClose":6.9,"halted":0,"volume":608000,"delay":0,"changeRate":0.014492753623188354,"floatShares":815000000,"shares":815000000,"eps":-0.392324,"marketStatus":"休市中","change":0.1,"latestTime":"02-13 16:08:09","open":6.88,"high":7,"low":6.78,"amount":4165455,"amplitude":0.031884,"askPrice":7,"askSize":29000,"bidPrice":6.87,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.335,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771205400000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":6.9,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":0.6339276405756139,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477/wiki","defaultTab":"wiki","newsList":[{"id":"2611958973","title":"每日卖空追踪 | 歌礼制药-B 02月12日卖空量成交4万股，卖空比例为0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611958973","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611958973?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:30","pubTimestamp":1770885024,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间02月12日，涨0.42%，卖空量成交4万股，较上一交易日减少91.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163255a6f28af4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212163255a6f28af4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","BK1161","01672","01477","BK1191"],"gpt_icon":0},{"id":"2611597393","title":"歌礼制药-B02月12日获主力加仓207.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611597393","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611597393?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884146,"startTime":"0","endTime":"0","summary":"02月12日, 歌礼制药-B股价涨0.42%，报收16.84元，成交金额8669.6万元，换手率0.50%，振幅6.44%，量比0.90。歌礼制药-B今日主力资金净流入207.8万元，上一交易日主力净流入461.1万元。该股近5个交易日上涨21.89%，主力资金累计净流入2654.8万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入3248.6万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161957a49b8f05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161957a49b8f05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","BK1574","BK1191","BK1161","01477","BK1515"],"gpt_icon":0},{"id":"2610935658","title":"麦德里格尔制药与苏州瑞博达成肝病项目授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2610935658","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610935658?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:31","pubTimestamp":1770805860,"startTime":"0","endTime":"0","summary":"麦德里格尔制药（Madrigal Pharmaceuticals）周三宣布，已与中国苏州瑞博生物技术股份有限公司及其子公司瑞博库制药签署全球独家授权协议，涉及6 个临床前小干扰 RNA（siRNA）项目，用于治疗一类肝脏疾病。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-11/doc-inhmmvzi4711702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2610057672","title":"歌礼制药-B(01672)：选定口服胰淀素受体激动剂多肽ASC36进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2610057672","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610057672?lang=zh_cn&edition=full","pubTime":"2026-02-11 07:06","pubTimestamp":1770764769,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，公司董事会宣布已选定其首款口服胰淀素受体激动剂多肽ASC36口服片进行临床开发。歌礼预计将于2026年第二季度向美国食品药品监督管理局递交ASC36口服片治疗肥胖症的新药临床试验申请。ASC36片亦显著减少了食物摄入。与近期获FDA批准的一款GLP-1R激动剂多肽相比，凭借潜在更优的口服生物利用度和疗效，预计ASC36口服片的给药剂量更低。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","01477","BK1191","01672","BK1161"],"gpt_icon":0},{"id":"2610648244","title":"歌礼制药-B(01672)完成配售6925.6万股股份 净筹约8.35亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610648244","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610648244?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:32","pubTimestamp":1770715961,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，已于2026年2月10日完成配售合共6925.6万股股份，每股配售价12.18港元，净筹约8.35亿港元，约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试验的准备、基础工作及启动，约10%建议用作营运资金及其他一般公司用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","01477","BK1191","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2610003646","title":"每日卖空追踪 | 歌礼制药-B 02月10日卖空量成交20.9万股，卖空比例为4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610003646","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610003646?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:30","pubTimestamp":1770712225,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间02月10日，涨5.15%，卖空量成交20.9万股，较上一交易日减少7.93%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163313a492b9a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163313a492b9a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","BK1161","BK1191","01477","01672"],"gpt_icon":0},{"id":"2610649887","title":"歌礼制药-B02月10日获主力加仓1393.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610649887","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610649887?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:15","pubTimestamp":1770711339,"startTime":"0","endTime":"0","summary":"02月10日, 歌礼制药-B股价涨5.15%，报收17.14元，成交金额8694.2万元，换手率0.51%，振幅6.75%，量比1.15。歌礼制药-B今日主力资金净流入1393.0万元，连续7日净流入，上一交易日主力净流入51.3万元。该股近5个交易日上涨31.57%，主力资金累计净流入2449.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2943.0万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161831a6e99934&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161831a6e99934&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01672","BK1191","01477","BK1515","BK1161"],"gpt_icon":0},{"id":"2610884649","title":"歌礼制药-B再涨超6% ASC30加速全球III期临床 机构称BD潜力较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2610884649","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610884649?lang=zh_cn&edition=full","pubTime":"2026-02-10 14:52","pubTimestamp":1770706348,"startTime":"0","endTime":"0","summary":"歌礼制药-B再涨超6%，截至发稿，涨5.52%，报17.2港元，成交额6945.8万港元。消息面上，GIC在歌礼制药最新一轮配售中获得头部分配额度，将助力ASC30加速全球III期临床推进。交易完成后，GIC持有歌礼制药6.42%股权。东方证券表示，ASC30减重数据优越，安全性良好，且分子专利已获美国授权，BD潜力较大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210150504a49257bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210150504a49257bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1161","01672","01477","BK1515","BK1574"],"gpt_icon":0},{"id":"2610323936","title":"每日卖空追踪 | 欧康维视生物-B 02月09日卖空量成交4.4万股，卖空比例为5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610323936","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610323936?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:30","pubTimestamp":1770625822,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间02月09日，涨0.29%，卖空量成交4.4万股，较上一交易日减少60.36%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163640a48e5ac4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163640a48e5ac4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2610769481","title":"国内制药行业首台自适应变工况高温蒸汽热泵投运落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2610769481","media":"‌仪器网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610769481?lang=zh_cn&edition=full","pubTime":"2026-02-09 13:04","pubTimestamp":1770613441,"startTime":"0","endTime":"0","summary":"近日，东方电气集团所属东方电机自主研制的高温蒸汽热泵机组，在国药太极涪陵药厂顺利投运。据悉，这是国内制药行业首台自适应变工况吨级超高温蒸汽热泵，它的成功投运，标志着东方电气在医药行业余热高效利用领域取得重要突破，也为医药行业绿色节能转型提供了新路径。目前，东方电气这款高温蒸汽热泵所产蒸汽参数，可满足制药、酿酒、化工、食品、印染等多个行业的主流工艺需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209131043a48d9aa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209131043a48d9aa0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1546","01072","BK1522","BK1574","01477","BK1205","BK1191"],"gpt_icon":0},{"id":"1116933064","title":"港股异动 | 歌礼制药盘中涨超8%，GIC斥资7.81亿港元增持歌礼制药，持股比例已达6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116933064","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116933064?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:01","pubTimestamp":1770602515,"startTime":"0","endTime":"0","summary":"2月9日，$歌礼制药-B$盘中涨超8%，GIC斥资7.81亿港元增持歌礼制药，持股比例已达6.42%。消息面上，2月6日，$港交所$披露的信息显示，新加坡政府投资基金以每股均价12.18港元的价格，斥资约7.81亿港元买入歌礼制药6412.8万股新股。交易完成后，GIC持有歌礼制药6.42%股权。公开资料显示，此次入股源于歌礼制药近期完成对配股计划。GIC在此轮配售中获得头部分配额度。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8173ebb445828bbdab4a68b6f572d4e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4104","BK1515","01477","BK4585","BK1574","BK4588","BK1191","01672"],"gpt_icon":0},{"id":"2610501497","title":"港股异动 | 歌礼制药-B(01672)早盘涨近9% GIC斥资7.81亿港元增持歌礼制药 持股比例已达6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610501497","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610501497?lang=zh_cn&edition=full","pubTime":"2026-02-09 09:43","pubTimestamp":1770601432,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘涨近9%，截至发稿，涨8.29%，报16.46港元，成交额1428.9万港元。消息面上，2月6日，港交所披露的信息显示，新加坡政府投资基金以每股均价12.18港元的价格，斥资约7.81亿港元买入歌礼制药6412.8万股新股。交易完成后，GIC持有歌礼制药6.42%股权。公开资料显示，此次入股源于歌礼制药近期完成对配股计划。GIC在此轮配售中获得头部分配额度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8173ebb445828bbdab4a68b6f572d4e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","BK4104","BK1161","GIC","BK1191","BK4588","VT","VXUS","BK4585","01477","01672"],"gpt_icon":0},{"id":"2609596974","title":"歌礼制药-B(01672.HK)获GIC Private Limited增持6412.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596974","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609596974?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:17","pubTimestamp":1770383821,"startTime":"0","endTime":"0","summary":"格隆汇2月6日丨根据联交所最新权益披露资料显示，2026年2月3日，歌礼制药-B(01672.HK)获GIC Private Limited在场内以每股均价12.18港元增持6412.8万股，涉资约7.81亿港元。\r\n\r\n　　增持后，GIC Private Limited最新持股数目为6412.8万股，持股比例为6.42%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202602/06/20260206499677.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202602/06/20260206499677.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260206/32004708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GIC","BK1161","BK4104","BK1574","BK1515","BK1191","01672","01477"],"gpt_icon":0},{"id":"2609593121","title":"每日卖空追踪 | 欧康维视生物-B 02月06日卖空量成交6.6万股，卖空比例为4.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609593121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609593121?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:30","pubTimestamp":1770366623,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间02月06日，跌1.27%，卖空量成交6.6万股，较上一交易日减少37.44%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163318a483cd85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206163318a483cd85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2609593104","title":"欧康维视生物-B02月06日主力净流出40.2万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2609593104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609593104?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:16","pubTimestamp":1770365762,"startTime":"0","endTime":"0","summary":"02月06日, 欧康维视生物-B股价跌1.27%，报收6.99元，成交金额1002.4万元，换手率0.18%，振幅4.38%，量比1.17。欧康维视生物-B今日主力资金净流出40.2万元，上一交易日主力净流出0万元。该股近5个交易日下跌5.41%，主力资金累计净流出504.8万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1001.8万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206162247a6dab3e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206162247a6dab3e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2609557291","title":"丰原药业：本公司代工生产丸红制药醋酸来法莫林注射用稀释液产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2609557291","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609557291?lang=zh_cn&edition=full","pubTime":"2026-02-06 15:30","pubTimestamp":1770363028,"startTime":"0","endTime":"0","summary":"根据合作协议，本公司代工生产丸红制药醋酸来法莫林注射用稀释液产品，丸红制药负责代工产品的销售覆盖和客户维护，本公司负责生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600020485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","01477","BK1574","BK1191","000153"],"gpt_icon":0},{"id":"2609554115","title":"诺华制药(NVS.US)全球首创自免新药在中国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2609554115","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609554115?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:48","pubTimestamp":1770360522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月6日，CDE网站显示，诺华制药(NVS.US)的伊利尤单抗(ianalumab)在中国申报上市。伊利尤单抗是诺华收购(MorphoSys)获得的一款靶向B淋巴细胞活化因子受体(BAFF-R)的全人源单抗，具有耗竭B细胞和抑制BAFF-R的双重作用机制，可用于治疗干燥综合征、免疫性血小板减少症(ITP)、系统性红斑狼疮(SLE)等多种自免疾病。该药物是首个完成III期研究的抗BAFF-R抗体。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4588","LU0320765489.SGD","IE00B4R5TH58.HKD","BK4578","01477","BK4585","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE00BJT1NW94.SGD","NVS","BK4532","IE0009355771.USD","BK4007","BK1191","LU0208291251.USD"],"gpt_icon":0},{"id":"2609301751","title":"歌礼制药-B盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301751?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:59","pubTimestamp":1770260396,"startTime":"0","endTime":"0","summary":"2026年02月05日早盘10时59分，歌礼制药-B股票出现波动，股价大幅下跌5.30%。截至发稿，该股报13.220港元/股，成交量84.7万股，换手率0.09%，振幅7.02%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。歌礼制药-B股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，银诺医药-B、药捷安康-B、中生北控生物科技涨幅较大，振幅较大的相关个股有银诺医药-B、北海康成-B、MIRXES-B，振幅分别为20.06%、16.50%、10.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205105957a6d52827&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205105957a6d52827&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01672","01477","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2608362077","title":"复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362077","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608362077?lang=zh_cn&edition=full","pubTime":"2026-02-04 21:37","pubTimestamp":1770212245,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，复星医药在互动平台回答投资者提问时表示，公司自1994年创立于上海，是一家植根中国、创新驱动的全球化医药健康产业集团。目前，公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务；其中，制药是公司的核心主营业务，也是公司品牌建设的重要承载。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641720167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0028","BK4585","BK1222","BK1583","159760","BK0196","BK1100","159883","09997","BK0175","BK1574","BK1515","LABU","02196","BK1191","BK0183","BK1593","BK4581","01477","BK0187","BK0060","09996","BK0096","600196","BK4588","BK0012","XBI","BK0188","XLV"],"gpt_icon":0},{"id":"2608013353","title":"仿制药冲击加剧 诺华制药(NVS.US)预警2026年利润将下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2608013353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608013353?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:48","pubTimestamp":1770191316,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月4日美股盘前，诺华制药公布2025年第四季度业绩。诺华公司预计今年利润将出现下滑，原因是公司的部分畅销药物将进一步受到仿制药竞争冲击。随着Entresto及其他老牌畅销药受到仿制药竞争者冲击，首席执行官Vas Narasimhan专注于创新药物的战略今年将面临考验。诺华已承诺在美国新建七处生产设施，这是其斥资230亿美元扩大该国制造规模计划的一部分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","01477","BK1191","LU0070302665.USD","IE00B2B36J28.USD","BK1574","BK4578","BK4532","IE0009355771.USD","IE00BJT1NW94.SGD","LU0208291251.USD","BK4007","IE00BFTCPJ56.SGD","BK4588","NVS","IE00B4R5TH58.HKD","LU0320765489.SGD","LU0211331839.USD","BK4585","IE00BJJMRZ35.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.0014},{"period":"1month","weight":-0.1184},{"period":"3month","weight":-0.1765},{"period":"6month","weight":-0.359},{"period":"1year","weight":0.7588},{"period":"ytd","weight":-0.0541}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.016},{"period":"3month","weight":-0.0187},{"period":"6month","weight":0.0513},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0365}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.049735},{"month":3,"riseRate":0.6,"avgChangeRate":0.058111},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}